Digestive tolerance of inulin-type fructans: a double-blind, placebo-controlled, cross-over, dose-ranging, randomized study in healthy volunteers

被引:43
|
作者
Bruhwyler, Jacques [3 ]
Carreer, Fabienne [3 ]
Demanet, Etienne [2 ]
Jacobs, Heidi [1 ]
机构
[1] Cosucra Grp Warcoing Sa, B-7740 Warcoing, Belgium
[2] ResearchLink Sprl, Thuin, Belgium
[3] Squarepoint Pointcarre Sprl, Ecaussinnes, Belgium
关键词
Inulin; fructan; tolerance; gastro-intestinal; healthy volunteers; HUMAN COLONIC MICROBIOTA; FECAL BIFIDOBACTERIA; DIETARY MODULATION; CHICORY INULIN; OLIGOFRUCTOSE; OLIGOSACCHARIDES; GLUCOSE; FIBER;
D O I
10.1080/09637480701625697
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Background Similar to other indigestible carbohydrates or dietary fibres, a consumption of too large quantities of inulin-type fructans may cause some digestive problems. Aim To compare the digestive tolerance of inulin-type fructans, administered during 2 weeks, at different doses. Methods Eighty-four healthy volunteers (aged 18-45 years, mean body mass index 25.1 kg/m2 and mean total fibre consumption 12 g) were included in a double-blind, placebo-controlled, randomized, cross-over study comparing Fibrulose F97 (5 and 20 g/day), Fibruline Instant (5, 10 and 20 g/day) and Fibruline XL (10 g/day) (degrees of polymerization respectively equal to 2-20, 2-60 with an average of 10, and 2-60 with an average 20) to placebo. The study was decomposed into five 2-week periods: placebo run-in, treatment 1, placebo washout, treatment 2, placebo run-out. The following symptoms were assessed using visual analogue scales: flatulence, rumbling, bloating, abdominal pain, abdominal cramps, nausea, stool frequency and stool consistency. The primary variable was the mean difference between treatment and placebo in terms of tolerance (sum of the eight visual analogue scales). Results The three products tended to increase digestive symptoms whatever the dose but the change was mild (maximum, +19 mm on the 800-mm scale) and significant (P0.001) for Fibruline Instant at 20 g/day only. At 20 g/day, a statistically significant difference between Fibruline Instant and Fibrulose F97 was demonstrated (P=0.011). There was a dose-effect relationship both for Fibrulose F97 (P0.05) and Fibruline Instant (P=0.042). All the other tendencies were non-significant. Conclusions The three different inulin-type fructans were very well tolerated.
引用
收藏
页码:165 / 175
页数:11
相关论文
共 50 条
  • [1] Acute fiber supplementation with inulin-type fructans curbs appetite sensations: a randomized, double-blind, placebo-controlled study
    Salmean, Younis A.
    FOOD & NUTRITION RESEARCH, 2017, 61
  • [2] Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo-controlled, randomized, double-blind, cross-over study
    Laine, Fabrice
    Laviolle, Bruno
    Bardou-Jacquet, Edouard
    Fatih, Nadia
    Jezequel, Caroline
    Collet, Nicolas
    Ropert, Martine
    Morcet, Jeff
    Hamon, Catherine
    Reymann, Jean-Michel
    Loreal, Olivier
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 (05) : 567 - 573
  • [3] The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers
    Ellidokuz, E
    Kaya, D
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (01) : 151 - 155
  • [4] Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    Goodman, A. D.
    Cohen, J. A.
    Cross, A.
    Vollmer, T.
    Rizzo, M.
    Cohen, R.
    Marinucci, L.
    Blight, A. R.
    MULTIPLE SCLEROSIS, 2007, 13 (03): : 357 - 368
  • [5] EFFECTS OF PROPAFENONE ON VENTRICULAR ARRHYTHMIAS - DOUBLE-BLIND, PARALLEL, RANDOMIZED, PLACEBO-CONTROLLED DOSE-RANGING STUDY
    SINGH, BN
    KAPLINSKY, E
    KIRSTEN, E
    GUERRERO, J
    AMERICAN HEART JOURNAL, 1988, 116 (06) : 1542 - 1551
  • [6] A dose-ranging study of midazolam for postoperative sedation of patients: A randomized, double-blind, placebo-controlled trial
    Hanaoka, K
    Namiki, A
    Dohi, S
    Koga, Y
    Yuge, O
    Kayanuma, Y
    Hidaka, K
    Kusunoki, T
    CRITICAL CARE MEDICINE, 2002, 30 (06) : 1256 - 1260
  • [7] CYCLANDELATE IN DIABETIC NEUROPATHY - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSS-OVER STUDY
    HEIMANS, JJ
    DRUKARCH, B
    MATTHAEI, I
    IJFF, GA
    BERTELSMANN, FW
    STRIJERS, RLM
    NAUTA, J
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 (06): : 483 - 486
  • [8] Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study
    G. S. Ungvari
    Helen F. K. Chiu
    Lok Yee Chow
    Benjamin S. T. Lau
    Wai Kwong Tang
    Psychopharmacology, 1999, 142 : 393 - 398
  • [9] XIMOPROFEN IN ANKYLOSING-SPONDYLITIS - A DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-RANGING STUDY
    DOUGADOS, M
    NGUYEN, M
    CAPORAL, R
    LEGEAIS, J
    BOUXINSAUZET, A
    PELLEGRIGUEGNAULT, B
    GOMENI, C
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1994, 23 (05) : 243 - 248
  • [10] DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF ADENOSINE IN PATIENTS WITH SUPRAVENTRICULAR TACHYCARDIA
    CARUSO, AC
    MILES, WM
    KLEIN, LS
    ZIPES, DP
    CLINICAL RESEARCH, 1989, 37 (04): : A874 - A874